Inhibitors of hepatitis C virus

摘要

The invention provides compounds of formula (I):;
wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

主权项

1. A compound of formula (I):wherein:
R1 is selected from C1-6alkyl, phenyl, C3-6cycloalkyl, heteroaryl, and heterocycle; wherein C1-6alkyl is optionally substituted with —ORq, wherein Rq is hydrogen or C1-3alkyl; R2 is selected from hydrogen and C1-6alkyl; R3 is selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl,—C(O)OC3-6cycloalkyl, —C(O)NRaRb, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, and —S(O)2C1-3alkyl; wherein
Ra and Rb are independently hydrogen or C1-6alkyl; R4 is —C(O)R5 or —S(O)2R6; R5 is selected from C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy, —C(RkRd)NReRf, —NRgRh, heteroaryl, heterocycle, —CH2-heteroaryl, and phenyl; wherein
C1-6alkyl is optionally substituted with one or two substituents independently selected from —ORc, —S(O)2C1-3alkyl, —NHC(O)C1-3alkyl, and —NHC(O)OC1-3alkyl;C1-6alkoxy is optionally substituted with —ORd;C3-6cycloalkyl is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, NRjRm, —ORn, and halo;any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, —C(O)OC1-3alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —C(O)NHC1-6alkyl, —C(O)NHC3-6cycloalkyl, and —S(O)2C1-3alkyl;
wherein any —C(O)C1-6alkyl is optionally substituted with —NHC(O)OC1-3alkyl, —ORn, —NRdRe, or heterocycle,any —C(O)C3-6cycloalkyl is optionally substituted with one or two C1-3alkyl, andany —C(O)NHC1-6alkyl is optionally substituted with —ORn or C3-6cycloalkyl;any heteroaryl is optionally substituted with C1-6alkyl or halo;Rc is independently selected from hydrogen, C1-6alkyl, and phenyl;Rd is independently hydrogen or C1-6alkyl;Re is independently hydrogen or C1-6alkyl;Rf is independently selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, and —C(O)C1-6alkyl;Rn is independently hydrogen or C1-3alkyl;Rk is independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl, and —CH2ORn;Rg is independently hydrogen or C1-6alkyl;Rh is independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, and —S(O)2C1-3alkyl, wherein C1-6alkyl is optionally substituted with —ORd;Rj is independently hydrogen or C1-6alkyl;Rm is independently selected from hydrogen, C1-6alkyl, —C(O)OC1-6alkyl, and —C(O)C1-6alkyl; R6 is selected from C1-6alkyl, C3-6cycloalkyl, phenyl, and a heteroaryl ring; R7, R8, and R11 are independently selected from halo, C1-6alkyl, C1-6alkoxy, —C(O)ORn, —CH2NRaRb, and —CN, wherein C1-6alkyl and C1-6alkoxy are optionally substituted with one, two, three, four, or five halo, and wherein C1-6alkoxy is optionally substituted with —ORd; R9 is independently selected from C1-6alkyl, —CH2ORn, —C(O)NRnRp, and C(O)ORn, wherein C1-6alkyl is optionally substituted with —S(O)2C1-3alkyl or with —SC1-3alkyl;
Rp is independently hydrogen or C1-3alkyl; R10 is selected from hydrogen, halo, C1-6alkyl, —C(O)ORc, —C(O)NRaRb, —CH2NRaRb, C3-6cycloalkyl, and —CN; W′, X′, Y′, and Z′ are each carbon wherein each carbon atom is bonded to hydrogen or to R11; W, X, Y, and Z are each carbon wherein each carbon atom is bonded to hydrogen or to R7; Am is —NHC(O); Q, U, and V are each carbon wherein each carbon atom is bonded to hydrogen or to R8, T is nitrogen; and a, b, c, and d are independently 0, 1, or 2;or a pharmaceutically-acceptable salt or stereoisomer thereof.